Healthcare Industry News: stapler
News Release - April 23, 2009
Covidien Launches Duet TRS(TM) Reload with Tissue Reinforcement
Innovative Endoscopic stapler Provides Support throughout the Critical Wound-Healing PeriodPHOENIX--(HSMN NewsFeed)--Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Surgical Devices business unit has launched the Duet TRS(TM) reload with tissue reinforcement. The product was introduced to hundreds of surgeons at the annual convention of the Society of Gastrointestinal and Endoscopic Surgeons (SAGES) in Phoenix. The device is now available in the United States and throughout the world.
“The state-of-the-art Duet TRS reload satisfies the surgeon’s need for universal applicability, as the reinforcement material is already integrated into the single use loading unit (SULU), and it provides customers with the added value of convenience and increased operating room efficiency,” said Michael Tarnoff, MD, FACS, Chief Medical Officer & VP Medical Affairs, Surgical Devices, Covidien. “After yesterday’s launch of SILS(TM) Port and today’s introduction of Duet TRS reload, tonight we will present an educational symposium as part of our Innovation: Delivered theme at SAGES. Presentations will include video demonstrations of both products and a question-and-answer session with the audience. Covidien is not just ‘talking’ about innovation. We are delivering innovative devices that are designed to improve patient outcomes,” added Dr. Tarnoff.
The Duet TRS reload offers preloaded tissue reinforcement on the Endo GIA(TM) Universal range of laparoscopic staplers. The reinforcement material is a synthetic absorbable polymer that is preloaded on each SULU. The proprietary fixation of the reinforcement material keeps it flat and secure during placement and manipulation on the tissue, which is a key benefit unique to this offering. The reinforcement material and anchoring sutures that secure the material on the Duet TRS reloads are made of Biosyn(TM) polymer, which has been sold by Covidien for nearly 10 years. Studies indicate that the absorbable material can be expected to retain measurable mechanical strength through 14 days and that absorption is essentially complete between 90 and 110 days.
More information on Duet TRS reload can be found by visiting www.duettrs.com
ABOUT COVIDIEN:
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Source: Covidien
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.